aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma announced it will advance efzofitimod development in pulmonary sarcoidosis following a Type C FDA meeting. The company plans to submit an IND in June 2026 for a Phase 3 study using FVC as primary endpoint and KSQ-Lung as secondary endpoint. The company ended Q1 2026 with $68.3 million in cash and is on track to complete enrollment in its Phase 2 SSc-ILD study in H1 2026.

05/15/2026, 8:00 AM • GlobeNewswire

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

04/08/2026, 1:00 PM • GlobeNewswire

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.

12/06/2025, 12:58 PM • GlobeNewswire

ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights

A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod, with investors having until December 8, 2025 to apply as lead plaintiff.

12/06/2025, 8:53 AM • GlobeNewswire

מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - ATYR

Rosen Law Firm alerts ATyr Pharma investors about a securities class action lawsuit deadline on December 8, 2025, related to allegedly misleading statements about the effectiveness of the drug Efzofitimod.

12/05/2025, 9:38 PM • GlobeNewswire

ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - ATYR

Rosen Law Firm is pursuing a securities class action against aTyr Pharma for allegedly providing false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16, 2025 to September 12, 2025.

12/05/2025, 5:57 PM • GlobeNewswire

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16-September 12, 2025.

12/05/2025, 12:00 PM • GlobeNewswire

Holzer & Holzer, LLC Reminds Investors of Upcoming December 8, 2025 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Marex, Inc. (MRX), aTyr Pharma, Inc. (ATYR), WPP plc (WPP) , and Cepton, Inc. (CPTN)

Law firm Holzer & Holzer reminds investors of upcoming December 8, 2025 lead plaintiff deadlines for shareholder class action lawsuits against multiple companies, alleging false statements and potential financial misconduct.

12/05/2025, 8:00 AM • GlobeNewswire

DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts shareholders about potential securities fraud class action lawsuits for multiple companies, citing misleading statements and undisclosed information during specific class periods.

12/03/2025, 1:40 PM • GlobeNewswire

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Faruqi & Faruqi is investigating potential securities claims against aTyr Pharma after the company's stock dropped 83.25% following disappointing clinical trial results for its drug Efzofitimod, which failed to demonstrate significant steroid reduction in patients.

11/29/2025, 8:48 AM • GlobeNewswire

ATYR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

Rosen Law Firm is notifying investors of a securities class action lawsuit against aTyr Pharma regarding potential misleading statements about their drug Efzofitimod during the period of January 16, 2025 to September 12, 2025.

11/29/2025, 7:11 AM • GlobeNewswire

התראת מועד לתביעה נגד ATYR: רוזן, יועץ מוביל למשקיעים, מעודד את משקיעי aTyr Pharma, Inc לקבל ייעוץ לפני המועד החשוב בתביעה ייצוגית בניירות ערך - ATYR

Rosen Law Firm reminds aTyr Pharma investors of an important December 8, 2025 deadline for a securities class action lawsuit, alleging the company made misleading statements about the effectiveness of drug Efzofitimod.

11/29/2025, 7:11 AM • GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors

The Portnoy Law Firm is advising aTyr Pharma investors about a potential class action lawsuit related to securities purchased between January 16 and September 12, 2025, following a failed Phase 3 clinical trial for efzofitimod.

11/25/2025, 9:00 AM • GlobeNewswire

Bragar Eagel & Squire, P.C. Urges Investors of aTyr, Marex, Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

Law firm alerts investors about potential class action lawsuits for four companies involving alleged financial misrepresentations, misleading statements, and potential securities fraud during specific class periods in 2024-2025.

11/24/2025, 5:32 PM • GlobeNewswire

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

Rosen Law Firm is notifying investors who purchased aTyr Pharma stock between January 16 and September 12, 2025, about a potential securities class action lawsuit regarding allegedly misleading statements about the drug Efzofitimod's efficacy.

11/23/2025, 1:15 PM • GlobeNewswire